JT Stratford LLC Takes $288,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

JT Stratford LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,648 shares of the biotechnology company's stock, valued at approximately $288,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Coppell Advisory Solutions LLC acquired a new stake in shares of Exelixis in the 4th quarter worth approximately $25,000. Colonial Trust Co SC grew its holdings in Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 765 shares during the last quarter. Principal Securities Inc. increased its position in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after buying an additional 373 shares during the period. Kestra Investment Management LLC acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $39,000. Finally, UMB Bank n.a. lifted its position in shares of Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock worth $45,000 after buying an additional 553 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Price Performance

Shares of NASDAQ:EXEL traded down $0.12 during mid-day trading on Wednesday, hitting $42.98. The company had a trading volume of 1,021,054 shares, compared to its average volume of 2,301,981. Exelixis, Inc. has a one year low of $20.14 and a one year high of $48.85. The firm has a fifty day moving average price of $38.14 and a 200 day moving average price of $36.23. The company has a market capitalization of $11.72 billion, a PE ratio of 24.29, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on EXEL shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 price target on shares of Exelixis in a report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Exelixis in a research report on Thursday, March 27th. Piper Sandler upped their target price on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Citigroup upped their price objective on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Finally, Stephens reiterated an "equal weight" rating and issued a $29.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $38.94.

Insider Buying and Selling at Exelixis

In other news, EVP Patrick J. Haley sold 10,000 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now owns 341,028 shares of the company's stock, valued at approximately $13,231,886.40. The trade was a 2.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 8,768 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the transaction, the director now owns 356,605 shares in the company, valued at $13,479,669. This represents a 2.40% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 459,276 shares of company stock valued at $20,945,859 in the last three months. Company insiders own 2.82% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.